# Protagenic Therapeutics, Inc.\\new: financial statements, quarterly

PTIX · OTC · CIK 1022899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/ptix.md) · [Financials](/companies/ptix/financials.md) · [Filings](/companies/ptix/filings.md) · [Insiders](/companies/ptix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ptix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001493152-24-045913.md) | [0.0 d](/filings/0001641172-25-001600.md) | [0.0](/filings/0001641172-25-009923.md) | [0.0](/filings/0001493152-24-032349.md) | [0.0](/filings/0001493152-24-045913.md) | [0.0 d](/filings/0001641172-25-001600.md) | [0.0](/filings/0001641172-25-009923.md) | [0.0](/filings/0001641172-25-027041.md) | [0.0 d](/filings/0001493152-25-025201.md) | [0.0 d](/filings/0001493152-26-009301.md) | [0.0 d](/filings/0001493152-26-038255.md) | not reported |
| Research and development | $k | [1,124](/filings/0001493152-24-045913.md) | [1,012 d](/filings/0001641172-25-001600.md) | [1,461](/filings/0001641172-25-009923.md) | [19.1](/filings/0001641172-25-027041.md) | [17.0](/filings/0001493152-25-025201.md) | [135](/filings/0001493152-26-009301.md) | [880](/filings/0001641172-25-009923.md) | [394](/filings/0001493152-26-039221.md) | [273](/filings/0001493152-25-025201.md) | [154](/filings/0001493152-26-009301.md) | [80.8 d](/filings/0001493152-26-038255.md) | [110](/filings/0001493152-26-039221.md) |
| Operating income | $k | [(1,432)](/filings/0001493152-24-045913.md) | [(1,212) d](/filings/0001641172-25-001600.md) | [(1,738)](/filings/0001641172-25-009923.md) | [(322)](/filings/0001641172-25-027041.md) | [(355)](/filings/0001493152-25-025201.md) | [(401)](/filings/0001493152-26-009301.md) | [(1,448)](/filings/0001641172-25-009923.md) | [(1,208)](/filings/0001493152-26-039221.md) | [(1,114)](/filings/0001493152-25-025201.md) | [(925)](/filings/0001493152-26-009301.md) | [(120) d](/filings/0001493152-26-038255.md) | [(961)](/filings/0001493152-26-039221.md) |
| Interest expense | $k | [32.0](/filings/0001493152-23-041032.md) | [12.9 d](/filings/0001493152-24-019018.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | [2.5](/filings/0001641172-25-027041.md) | [(2.5)](/filings/0001493152-25-025201.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,397)](/filings/0001493152-24-045913.md) | [(1,676) d](/filings/0001641172-25-001600.md) | [(1,724)](/filings/0001641172-25-009923.md) | [(324)](/filings/0001493152-26-009301.md) | [(582)](/filings/0001493152-26-009301.md) | [(850)](/filings/0001493152-26-009301.md) | [(1,440)](/filings/0001641172-25-009923.md) | [(5,058)](/filings/0001493152-26-039221.md) | [(869)](/filings/0001493152-26-009301.md) | [2,211](/filings/0001493152-26-009301.md) | [5,084 d](/filings/0001493152-26-038255.md) | [(964)](/filings/0001493152-26-039221.md) |
| Diluted EPS | $ per share | [(0.32)](/filings/0001493152-24-045913.md) | not reported | [(5.44)](/filings/0001641172-25-009923.md) | [(0.06)](/filings/0001641172-25-027041.md) | [(0.11)](/filings/0001493152-25-025201.md) | [(0.16)](/filings/0001493152-26-009301.md) | [(2.75)](/filings/0001641172-25-009923.md) | [(1.37)](/filings/0001493152-26-039221.md) | [(0.47)](/filings/0001493152-25-025201.md) | [1.14](/filings/0001493152-26-009301.md) | not reported | [(0.53)](/filings/0001493152-26-039221.md) |
| Basic EPS | $ per share | [(0.32)](/filings/0001493152-24-045913.md) | not reported | [(5.44)](/filings/0001641172-25-009923.md) | [(0.06)](/filings/0001641172-25-027041.md) | [(0.11)](/filings/0001493152-25-025201.md) | [(0.16)](/filings/0001493152-26-009301.md) | [(2.75)](/filings/0001641172-25-009923.md) | [(1.37)](/filings/0001493152-26-039221.md) | [(0.47)](/filings/0001493152-25-025201.md) | [1.14](/filings/0001493152-26-009301.md) | not reported | [(0.53)](/filings/0001493152-26-039221.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.2](/filings/0001493152-23-041032.md) | [1.3](/filings/0001641172-25-001600.md) | [0.8](/filings/0001493152-24-019933.md) | [0.9](/filings/0001493152-24-032349.md) | [1.1](/filings/0001493152-24-045913.md) | [1.8](/filings/0001641172-25-009923.md) | [0.0](/filings/0001493152-26-038255.md) | [4.1](/filings/0001641172-25-027041.md) | [2.7](/filings/0001493152-25-025201.md) | [2.2](/filings/0001493152-26-009301.md) | [1.5](/filings/0001493152-26-039221.md) | [0.6](/filings/0001493152-26-039221.md) |
| Current assets | $m | [5.4](/filings/0001493152-23-041032.md) | [4.2](/filings/0001641172-25-001600.md) | [2.5](/filings/0001493152-24-019933.md) | [1.4](/filings/0001493152-24-032349.md) | [1.4](/filings/0001493152-24-045913.md) | [1.9](/filings/0001641172-25-009923.md) | [0.1](/filings/0001493152-26-038255.md) | [4.3](/filings/0001641172-25-027041.md) | [2.9](/filings/0001493152-25-025201.md) | [2.3](/filings/0001493152-26-009301.md) | [1.5](/filings/0001493152-26-039221.md) | [0.7](/filings/0001493152-26-039221.md) |
| Total assets | $m | [5.4](/filings/0001493152-23-041032.md) | [4.3](/filings/0001641172-25-001600.md) | [2.6](/filings/0001493152-24-019933.md) | [1.5](/filings/0001493152-24-032349.md) | [1.5](/filings/0001493152-24-045913.md) | [2.0](/filings/0001641172-25-009923.md) | [0.1](/filings/0001493152-26-038255.md) | [6.5](/filings/0001641172-25-027041.md) | [5.0](/filings/0001493152-25-025201.md) | [4.4](/filings/0001493152-26-009301.md) | [3.7](/filings/0001493152-26-039221.md) | [2.8](/filings/0001493152-26-039221.md) |
| Current liabilities | $m | [1.3](/filings/0001493152-23-041032.md) | [0.7](/filings/0001641172-25-001600.md) | [0.4](/filings/0001493152-24-019933.md) | [0.7](/filings/0001493152-24-032349.md) | [0.8](/filings/0001493152-24-045913.md) | [0.9](/filings/0001641172-25-009923.md) | [5.0](/filings/0001493152-26-038255.md) | [10.5](/filings/0001641172-25-027041.md) | [9.7](/filings/0001493152-25-025201.md) | [6.8](/filings/0001493152-26-009301.md) | [1.0](/filings/0001493152-26-039221.md) | [1.1](/filings/0001493152-26-039221.md) |
| Total liabilities | $m | [1.3](/filings/0001493152-23-041032.md) | [0.7](/filings/0001641172-25-001600.md) | [0.4](/filings/0001493152-24-019933.md) | [0.7](/filings/0001493152-24-032349.md) | [0.8](/filings/0001493152-24-045913.md) | [0.9](/filings/0001641172-25-009923.md) | [5.0](/filings/0001493152-26-038255.md) | [10.5](/filings/0001641172-25-027041.md) | [9.7](/filings/0001493152-25-025201.md) | [6.8](/filings/0001493152-26-009301.md) | [1.0](/filings/0001493152-26-039221.md) | [1.1](/filings/0001493152-26-039221.md) |
| Shareholders' equity | $m | [4.2](/filings/0001493152-24-045913.md) | [3.7](/filings/0001641172-25-009923.md) | [(1.8)](/filings/0001493152-26-038255.md) | [(1.8)](/filings/0001493152-26-009301.md) | [(2.5)](/filings/0001493152-26-009301.md) | [(3.3)](/filings/0001493152-26-009301.md) | [(5.0)](/filings/0001493152-26-039221.md) | [(4.0)](/filings/0001493152-26-039221.md) | [(4.7)](/filings/0001493152-26-009301.md) | [(2.4)](/filings/0001493152-26-009301.md) | [2.6](/filings/0001493152-26-039221.md) | [1.7](/filings/0001493152-26-039221.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(656) d](/filings/0001493152-24-045913.md) | [(1,144) d](/filings/0001641172-25-001600.md) | [(1,659)](/filings/0001641172-25-009923.md) | [(246)](/filings/0001641172-25-027041.md) | [(186) d](/filings/0001493152-24-045913.md) | [(820) d](/filings/0001641172-25-001600.md) | [(1,068)](/filings/0001641172-25-009923.md) | [(1,751)](/filings/0001493152-26-039221.md) | [(812) d](/filings/0001493152-25-025201.md) | [(510) d](/filings/0001493152-26-009301.md) | [266 d](/filings/0001493152-26-038255.md) | [(944)](/filings/0001493152-26-039221.md) |
| Capital expenditure | $k | not reported | [94.0 d](/filings/0001641172-25-001600.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,318](/filings/0001493152-24-019933.md) | [4,331](/filings/0001493152-24-032349.md) | [4,331](/filings/0001493152-24-045913.md) | [317](/filings/0001641172-25-009923.md) | [5,396](/filings/0001641172-25-027041.md) | [5,396](/filings/0001493152-25-025201.md) | [5,396](/filings/0001493152-26-009301.md) | [523](/filings/0001641172-25-009923.md) | [3,701](/filings/0001493152-26-039221.md) | [1,849](/filings/0001493152-25-025201.md) | [1,935](/filings/0001493152-26-009301.md) | [1,810](/filings/0001493152-26-039221.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,810,208 at 2026-08-19, from the cover of the [10-Q filed 2026-08-19](/filings/0001493152-26-039221.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.